SEARCH

SEARCH BY CITATION

References

  • 1
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 4152.
  • 2
    Koike K. Antiviral treatment of hepatitis C: present status and future prospects. J Infect Chemother 2006; 12: 227332.
  • 3
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 4
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97103.
  • 5
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 6
    Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 2006; 26: 11191125.
  • 7
    Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peg interferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636641.
  • 8
    Iolascon A, Volinia S, Borriello A, Giordani L, Moretti A, Servedio V, et al. Genes transcriptionally modulated by interferon alpha2a correlate with the cytokine activity. Haematologica 2004; 89: 10461053.
  • 9
    Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529535.
  • 10
    Huang, Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, et al. Defective hepatic response to interferon and activation of suppressor signalling 3 in chronic hepatitis C. Gastroenterology 2007; 132: 733744.
  • 11
    Reid MC, Guo Z, Van Ness PH, O'Connor PG, Concato J. Are commonly ordered lab tests useful screens for alcohol disorders in older male veterans receiving primary care. Subst Abus 2005; 26: 2532.
  • 12
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29( suppl 1): S43S48.
  • 13
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Circulation 2005; 112: e285e290.
  • 14
    Ishak K, Baptista A, Bianch L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696669.
  • 15
    Chomczynsky P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156159.
  • 16
    Kwok S, Higuchi R. Avoiding false positive with PCR. Nature 1989; 339: 237238.
  • 17
    Viazov S, Zibert A, Ramakrishnan K, Widell A, Cavicchini A, Schreier E, et al. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods 1994; 48: 8192.
  • 18
    Vlotides G, Sorensen AS, Kopp F, Zitzmann K, Cengic N, Brand S, et al. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun 2004; 320: 10071014.
  • 19
    Livak KJ, Schmitteng TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 2001; 25: 402408.
  • 20
    Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 14991508.
  • 21
    Ghanim H, Aljada A, Daoud N, Deopurkar R, Chaudhuri A, Dandona P. Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects. Diabetologia 2007; 50: 278285.
  • 22
    Yao ZQ, Waggoner SN, Cruise MW, Hall C, Xie X, Oldach DW, et al. SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR ligation to inhibit T-cell function. J Virol 2005; 80: 8287.
  • 23
    Camma C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. HEPATOLOGY 2006; 43: 6471.
  • 24
    Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 10031008.
  • 25
    Lonardo A, Loria P, Adinolfi LE, Andreana A, Ruggiero G, Carulli N, et al. Hepatitis C virus-associated and metabolic steatosis. Different or overlapping diseases? Ann Ital Med Int 2005; 20: 1022.
  • 26
    Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. HEPATOLOGY 2006; 44: 16421655.
  • 27
    Asselah T, Rubbia-Brandt L, Marcellin P, Negro. F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123130.
  • 28
    Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840848.
  • 29
    Ratziu V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. HEPATOLOGY 2006; 44: 802805.
  • 30
    Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006; 24: 13491357.
  • 31
    Elsammak M, Refai W, Elsawaf A, Abdel-Fattah I, Abd Elatti E, Ghazal A, et al. Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin 2005; 21: 527534.
  • 32
    Miyoshi H, Fujie H, Shintani Y, Tsutsumi T, Shinzawa S, Makuuchi M, et al. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J Hepatol 2005; 43: 757763.